FDA Expands Approval of Groundbreaking Gene Therapy
A New Hope for Duchenne Muscular Dystrophy Patients The U.S. Food and Drug Administration (FDA) recently broadened its approval of Elevidys, a revolutionary gene therapy developed by Sarepta Therapeutics for Duchenne muscular dystrophy (DMD). This rare genetic muscle disease, primarily affecting boys, has long been a challenging condition to treat. Elevidys, costing $3.2 million per […]
